Medicare forced to cover unproven devices for four years, no cost review

What it does

This bill creates a fast-track Medicare coverage pathway for medical devices that the FDA has designated as 'breakthrough' innovations. Once a device receives FDA priority review and meets clinical criteria, Medicare must cover it automatically for four years while the agency decides whether to make coverage permanent—bypassing the normal lengthy review process. Device makers apply to Medicare for 'breakthrough' status; the agency has six months to decide and must explain any rejection.

Why we flagged it

The bill's core mechanism is a mandatory four-year Medicare coverage guarantee for FDA-designated breakthrough devices, bypassing standard cost-effectiveness review. This is functionally a coverage entitlement for a defined device category, not a procedural reform.

What the text implies

• Medicare's standard coverage review (National Coverage Determination) is designed to assess cost-effectiveness and clinical necessity; this bill guarantees payment for four years based on FDA priority designation alone, potentially shifting cost-benefit analysis burden to the back end of the transitional period.
• Device manufacturers have strong incentive to seek FDA priority review (which is discretionary) knowing it triggers automatic Medicare coverage; this may accelerate FDA priority designations for devices with marginal clinical advantage over existing alternatives.
• The bill requires Medicare to issue a final coverage decision before the four-year transitional period ends, but does not require that decision to be favorable—if Medicare denies coverage after four years, beneficiaries and providers face sudden coverage cliff.
• Aberrant billing review authority is discretionary and reactive; high-volume or off-label use of breakthrough devices during the four-year window may not be detected or corrected until after substantial spending has occurred.
• No explicit cap on total spending or per-device volume; if a breakthrough device is used at high frequency or for broader indications than FDA-approved labeling, Medicare liability is open-ended during the transitional period.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients gain faster access to potentially life-saving devices without waiting years for Medicare coverage decisions, a concrete public benefit. However, the bill guarantees Medicare payment for four years based primarily on FDA priority designation—a lower evidentiary bar than Medicare's usual cost-effectiveness and clinical necessity standards—creating risk that less-proven devices will be paid for at public expense, potentially inflating costs and crowding out other treatments.

Who stands to gain

• medical device manufacturers (especially those with FDA breakthrough designations)
• device distributors and suppliers
• hospitals and outpatient surgery centers (higher reimbursement certainty)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA), Medicare Part A and Part B, Device manufacturers, Pfizer (PFE), Humana (HUM), Boston Scientific (BSX), Align Technology (ALGN)

Where it stands

65 cosponsors: 33 Republicans, 32 Democrats.

• Sep 15, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 15, 2025 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”
• Sep 17, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Sep 17, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

30 lobbying clients named this bill on 43 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $11,347,988 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

Blake Moore, the sponsor, reported $1,475,500 in PAC receipts in the 2026 cycle. $34,000 of that came from 5 PACs tied to these lobbying clients.

• Philips Holding USA Inc. — $1,950,000 on 3 filings
• Advanced Medical Technology Assn — $1,913,000 on 2 filings
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing
• Boston Scientific Corporation — $1,212,000 on 2 filings
• Medtronic Inc — $1,180,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.